tbuckley/cabot-search huggingface dataset:
P1.04-017 The Survival of Our Patients Diagnosed with Lung Cancer in 2013
Authors: Sedat Altin, Cengiz Ozdemir, Celalettin Kocaturk, Murat Kiyik, Nur Urer, Mehmet Gunluoglu, Kaan Kara, Serap Hastürk, Yusuf Baser, Mehmet Bedirhan, Ibrahim Dincer
Journal: Journal of Thoracic Oncology (2017)
P3.02c-063 Lactate Dehydrogenase (LDH) as a Surrogate Biomarker to Checkpoint-Inhibitors for Patient with Advanced Non–Small-Cell Lung Cancer (NSCLC)
Authors: Am Martinez De Castro, Alejandro Navarro, Susana Cedres Perez, Alex Martinez, Nuria Pardo, Alberto Hernando, Carolina Ortiz, Fabiola Amair, M. Biosca, Juan Aguilar-Company, Eulalia Scheenaard, Sergi Recasens, Lluisa Carbonell, Andrea Retter, Sonia Martinez, Adelaida Piera, Sonia Valverde, Lidia Velez, Silvia García Matas, Marta Vilaro, Enriqueta Felip
Journal: Journal of Thoracic Oncology (2017)
P2.03b-035 EGFR FISH as Potential Predictor of Necitumumab Benefit with Chemotherapy in Squamous NSCLC: Subgroup Analyses from SQUIRE
Authors: Carlo Genova, Marileila Varella-Garcia, Christopher Rivard, Mark Socinski, Rebecca Hozak, Gu Mi, Raffael Kurek, Javad Shahidi, Luis Paz-Ares, Nick Thatcher, Fred R. Hirsch
Journal: Journal of Thoracic Oncology (2017)
P2.04-053 Surgery of Multiple Lung Metastases in Patients with Sarcomas and Epithelial Tumors
Authors: Evgeny Smolenov, Yury Ragulin, Vladimir Usachev, Aleksey Starodubtcev, Aleksander Popov, Aleksander Kurilchik, Ivan Zaborskiy
Journal: Journal of Thoracic Oncology (2017)
S44 Pseudomonas aeruginosa induces neutrophil cell death which is reversed by hypoxia
Authors: SP Williams, R Dickinson, SR Walmsley
Journal: Thorax (2016)

<h3>Introduction</h3> Neutrophils accumulate in the lungs of patients with bronchiectasis and cystic fibrosis, and the resulting inflammation causes tissue hypoxia. Neutrophils have a unique ability to survive and function in such hypoxic environments, a response regulated by the hypoxia-inducible transcription factor (HIF)/hydroxylase oxygen sensing pathway. <i>Pseudomonas aeruginosa</i> is an opportunistic pathogen which colonises patients with chronic lung disease, including cystic fibrosis. It secretes the toxin pyocyanin, which induces neutrophil apoptosis in an oxygen-dependent manner, as a means of immune-evasion. <i>P. aeruginosa </i>has recently been shown to possess hydroxylase-homologs, suggesting that prokaryotes may also have oxygen-sensing capabilities. A prolyl-hydroxylase (PHD)<i>-</i>deficient strain secretes higher levels of pyocyanin compared with wild-types. We hypothesised that PHD<i>-</i>deficient <i>P. aeruginosa </i>induces a higher degree of neutrophil death compared with an otherwise genetically identical wild-type strain. Furthermore, we postulated that the killing effects of these bacteria are reversed in hypoxia. <h3>Methods</h3> Human neutrophils were purified from healthy volunteers by discontinuous percoll gradients. PAO-1 and PHD-deficient strains were grown in lysogeny broth and equivalent growth curves confirmed. Supernatants from wild-type and PHD-deficient <i>P. aeruginosa</i> were harvested at two hours and then co-cultured with neutrophils in normoxia and hypoxia. Neutrophil viability and apoptosis was then assessed using AnnexinV/To-pro-3 staining on flow cytometry at three and five hours. <h3>Results</h3> Control neutrophils in normoxia saw a decrease in viability of 6% between three and five hours. Neutrophils treated with supernatant from the PHD-deficient strain experienced a decrease in viability from 3139 (± 968) cells at three hours to 2058 (± 586) at five hours – a decline of 34% (P &lt; 0.05). Normoxic neutrophils treated with the wild-type strain, however, saw a decrease of 21% (P &lt; 0.05). Hypoxic conditions reversed the killing effects of wild-type <i>P. aeruginosa: </i>after five hours neutrophils in normoxia experienced a 21% decrease in viability, whereas the viability of hypoxic cells only decreased by 8% (P &lt; 0.05). <h3>Discussion</h3> These data highlight the relationship between tissue oxygen tensions and host immunity and that bacteria have evolved virulence factors with novel mechanisms of action; namely preventing neutrophil survival at sites of inflammation. Moreover, the potential oxygen-sensing capabilities of prokaryotes are intricately linked to bacterial virulence.
P3.02c-019 The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes
Authors: Marina Serdarevic, Suzana Kukulj, Ante Rebic, Gordana Drpa, Bernard Budimir, Filip Popovic, Tea Lovric, Katherina Sreter, Miroslav Samarzija
Journal: Journal of Thoracic Oncology (2017)
Identification of Novel Mutations In Ribosomal Genes In Patients with Diamond Blackfan Anemia (DBA) In Germany and Genotype-Phenotype Correlation Analysis
Authors: Mihaela Pali, Jessica Moetter, Joerg Meerpohl, Mutlu Kartal, Alexandra Fischer, Sandra Urbaniak, Peter Noellke, Manfred Fliegauf, Lydie M. Da Costa, Charlotte M Niemeyer, Marcin W. Wlodarski
Journal: Blood (2010)
P2.01-007 Detection of Promoter DNA Methylation of APC, DAPK, and GSTP1 Genes in Tissue Biopsy and Matched Serum of Advanced Stage Lung Cancer Patients
Authors: Ashraf Ansari, Sachin Kumar, Vinod Kakaria, Anant Mohan, Kalpana Luthra, Ashish Upadhyay, Randeep Guleria
Journal: Journal of Thoracic Oncology (2017)
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia
Authors: Giorgia Simonetti, Antonella Padella, Ítalo Faria do Valle, Gabriele Fontanarosa, Elisa Zago, Marianna Garonzi, Cristina Papayannidis, Maria Chiara Abbenante, Giovanni Marconi, Viviana Guadagnuolo, Maria Chiara Fontana, Samantha Bruno, Anna Ferrari, Elisa Zuffa, Eugenia Franchini, Annalisa Astolfi, Elisa Dan, Barbara Sinigaglia, Ilaria Iacobucci, Simona Soverini, Michele Cavo, Emanuela Ottaviani, Alberto Ferrarini, Massimo Delledonne, Daniel Remondini, Giovanni Martinelli
Journal: Blood (2015)
Response of Elevated Serum Soluble Interleukin-2 Receptor (sIL-2R) and Overexpression of Glucose-6-Phosphate Dehydrogenase (G6PD) in Patients with Chronic Myelogenous Leukemia Treated with Imatinib Mesylate.
Authors: Eugene McPherson, M. Shanmughan, S.Y. Huang, J. Kleinfeld, E. Hazel, P. Tassy
Journal: Blood (2004)
P1.08-065 Resection of Isolated Brain Metastasis Improves Outcome of Non-Small-Cell Lung Cancer (NSCLC) Patients: A Retrospective Multicenter Study
Authors: Julia Fuchs, Martin Früh, Alexandros Papachristofilou, Lukas Bubendorf, Catherine Schill, Lorenz Jost, Alfred Zippelius, Sacha Rothschild
Journal: Journal of Thoracic Oncology (2017)
P121 Urban fine and coarse mode particulate matter differentially alter the maturation of monocyte-derived dendritic cells
Authors: TR Ho, N Camina, PE Pfeffer, EH Mann, IS Mudway, CM Hawrylowicz
Journal: Thorax (2016)

<h3>Background</h3> There is considerable evidence linking increased exposure to particulate matter (PM2.5 and PM10) to adverse respiratory outcomes, with patients with asthma and chronic obstructive pulmonary diseases (COPD) prone to more exacerbations and respiratory tract infections during pollution episodes. We have previously shown that peripheral human CD1c+ myeloid DCs, a key orchestrator of the adaptive immune response, promoted naive CD4+ T lymphocyte proliferation and increased expansion of potent inflammatory Th1 and Th17 effector cells when challenged with standard reference urban PM (SRM-1648a). However, monocyte-derived dendritic cells (MDDCs), which represent an inflammatory subset of DCs, may play a substantial role in lung inflammation. In this study, we investigated the effects of PM on MDDC maturation, focusing on responses to PM samples collected from the contemporary London airshed. <h3>Methods</h3> PM2.5 and PM10 from a high traffic roadside site in London were collected (2/1/2013 – 15/1/2014) and pooled to generate representative annual samples. SRM-1648a and SRM-2975 (diesel exhaust derived PM) were used as control samples. Differentiated MDDCs, derived from CD14+ monocytes incubated with IL-4 and GM-CSF for 6 days, were challenged with these PM samples, plus control PM samples at various concentrations (2.5–20 µg/ml) for 24 hours. DC expression of CD83, MHC-I and MHC-II were measured by flow-cytometry. <h3>Results</h3> Roadside PM10 and SRM-1648a exposure significantly increased the expression of MHC-II on MDDCs, whilst Roadside PM2.5 and SRM-2975 had no impact. There was also an increased expression of maturation marker CD83 when cells were exposed to Roadside PM10 and SRM-1648a, as well as Roadside PM2.5 at a higher concentration. However, exposure to all PM samples except for Roadside PM10 led to a significant decrease in MHC-I expression. <h3>Conclusion</h3> PM fractions containing coarse mode material (SRM-1648a and PM10) appeared more able to stimulate MDDC maturation than fine mode PM (SRM-2975 and PM2.5). There was a clear decrease in MHC-I expression after exposure to most PM samples. This may indicate that MDDCs DCs exposed to PM are less able to stimulate CD8+ T cells, resulting in recurring respiratory tract infections. Understanding the immunological effects of different particle types will help guide public health interventions.
Efficacy and safety of consecutive chemotherapy treatments for elderly patients with advanced or recurrent gastric cancer.
Authors: T. Kusumoto, E. Oki, S. Hiroshige, Y. Endo, H. Uchida, T. Matsumoto, H. Takeuchi, T. Matsushima, Y. Emi, H. Matsuura, Y. Muto, Y. Maehara
Journal: Journal of Clinical Oncology (2011)

e14586 Background: In recent years, the proportion of elderly patients has increased to more than 20% of the population in Japan. Three previous Japanese phase III trials on advanced or recurrent gastric cancer (ARGC) did not accrue patients who were more than 75 years old. Although the above trials showed that S-1 is an effective standard chemotherapeutic agent for ARGC, either dose reduction or prolonged duration of the treatment interval is generally applied to elderly patients. Methods: We conducted a retrospective review of the data of 102 patients with ARGC who received chemotherapy who were given S-1-containing regimens as first line; and irinotecan and paclitaxel as second or third-line treatments. The patients were categorized into a younger group (<75 years old, n = 74) and an elderly group (≥75 years old, n = 28). All drugs started to be administered based on their use in the previous trials and on the generally adopted clinical practice. The drug toxicity, the dose intensity, PFS and OS were compared between the two groups. Results: The incidence of adverse events was more frequent in the elderly group than in the younger group. However, the rates of hematological and non-hematological toxicities of higher than grade 3 were 37.5% and 25.0% in the elderly group, similar to those found in the younger group. The dose intensities of S-1 were 67% in the former group, compared with 74% in the latter (p < 0.05). Survival data showed that the MST was 472 days and the median PFS was 108 days for the first line treatments in the elderly patients, compared with 669 days and 123 days in the younger patients, were not significantly different. Conclusions: Adverse reactions were more frequently reported in the elderly group than in the younger group in spite of the dose reduction. However, the elderly patients tolerated intensive chemotherapy, with sufficient efficacy in cases that had neither severe general complications nor organ dysfunctions. A set of guidelines to recommend the dose of chemotherapeutic drugs for elderly patients are therefore considered to be needed in the future given the aging of society, and it may be possible to base these guidelines on the results of prospective trials for patients with ARGC.
Myocardial infarction after general anesthesia
Authors: S. Tarhan
Journal: JAMA (1972)

During 1967 and 1968, a total of 32,877 patients had general anesthesia at the Mayo Clinic; 422 had previous myocardial infarction. Of these 6.6% experienced another infarction during the first postoperative week. There was no relationship between incidence of postoperative reinfarction and type or duration of anesthesia. However, operations on the thorax and upper abdomen were followed by three times as many reinfarctions as operations at other sites. Patients who were operated on within three months of infarction had a 37% reinfarction rate. This rate decreased to 16% in patients at three to six months after infarction, and remained at 4% to 5% when infarction had occurred more than six months previously. A significantly higher number of myocardial infarctions occurred during the third postoperative day.
MA08.10 Detection of the T790M Mutation of EGFR in Plasma of Advanced NSCLC Patients with Acquired Resistance to EGFR-TKI (WJOG8014LTR)
Authors: Koichi Azuma, Takayuki Takahama, Kazuko Sakai, Masayuki Takeda, Toyoaki Hida, Masataka Hirabayashi, Tetsuya Oguri, Hiroshi Tanaka, Noriyuki Ebi, Toshiyuki Sawa, Akihiro Bessho, Motoko Tachihara, Hiroaki Akamatsu, Shuji Bandoh, Daisuke Himeji, Tatsuo Ohira, Mototsugu Shimokawa, Nobuyuki Yamamoto, Yoichi Nakanishi, Kazuhiko Nakagawa, Kazuto Nishio
Journal: Journal of Thoracic Oncology (2017)
MA06.05 Screening for Brain Metastases in Patients with Stage III NSCLC, MRI or CT? A Prospective Study
Authors: Janna Schoenmaekers, Lizza Hendriks, Paul Hofman, Gerben Bootsma, Marcel Westenend, Machiel De Booij, Wendy Schreurs, Ruud Houben, Dirk De Ruysscher, Anne-Marie Dingemans
Journal: Journal of Thoracic Oncology (2017)
Cerebrospinal Fluid Flow Cytometry Analysis in Newly Diagnosed Aggressive Non-Hodgkin Lymphomas at High Risk for Leptomeningeal Disease: Result of a Multicentric Prospective Italian Study.
Authors: Giulia Benevolo, Pietro Pioltelli, Michele Spina, Barbara Botto, Alessandra Stacchini, Andrea Evangelista, Pietro Bulian, Francesco Mannelli, Maria Cantonetti, Alice Di Rocco, Lorella Depaoli, Vincenzo Pavone, Nicola Di Renzo, Andres Ferreri, Marcella Arras, Enrico Pogliani, Umberto Vitolo
Journal: Blood (2009)
Diabetes Mellitus–Induced Microvascular Destabilization in the Myocardium
Authors: Rabea Hinkel, Andrea Howe, Simone Renner, Judy Ng, Seungmin Lee, Katharina Klett, Veronika Kaczmarek, Alessandra Moretti, Karl-Ludwig Laugwitz, Philipp Skroblin, Manuel Mayr, Hendrik Milting, Andreas Dendorfer, Bruno Reichart, Eckhard Wolf, Christian Kupatt
Journal: Journal of the American College of Cardiology (2017)
Sequential Topoisomerase I (Topo I) and Topoisomerase II (Topo II) Inhibitors in Relapsed/Refractory Aggressive NHL: Results of CALGN 59906, a Phase II Study of Doxorubicin and Topotecan.
Authors: Sonali M. Smith, Jeffrey L. Johnson, Donna Niedzwiecki, J. Paul Eder, George P. Canellos, Bruce D. Cheson, Nancy L. Bartlett
Journal: Blood (2004)
IMPROVED PROGNOSIS FOR PATIENTS WITH PRIMARY BILIARY CIRRHOSIS SHOWING RELEVANT BIOCHEMICAL RESPONSE TO UDCA. RESULTS OF A MULTICENTER LONG-TERM COHORT STUDY INVOLVING 375 PATIENTS
Authors: Edith M. Kuiper, Bettina E. Hansen, Richard A. de Vries, Janna W. den Ouden-Muller, Theo J. van Ditzhuijsen, Els B. Haagsma, Martin Houben, Ben J. Witteman, Karel J. Van Erpecum, Henk R. van Buuren
Journal: Hepatology (2008)
P2.03b-093 Validation and Performance of a Standardized ctDNA NGS Assay across Two Laboratories
Authors: Tim Forshew, Andrew Lawson, Sarah Smalley, Vincent Plagnol, John Calaway, Shannon Blais, Karen Howarth, Greg Jones, Michelle Pugh, Mikidachi Madi, Bradley Durham, Esther Musgrave-Brown, Sam Woodhouse, Nitzan Rosenfeld, Davina Gale, Emma Green, James Clark
Journal: Journal of Thoracic Oncology (2017)
Responding to Firearm Homicide in Urban Areas
Authors: Robert Steinbrook
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
The WT1 synonymous SNP rs16754 Is Associated with Higher mRNA Expression and Predicts Significantly Improved Outcome In Favorable-Risk Pediatric AML: a Report From the Children's Oncology Group
Authors: Phoenix A. Ho, Julia Kuhn, Robert B. Gerbing, Jessica A. Pollard, Rong Zeng, Kristen L. Miller, Nyla A. Heerema, Susana C. Raimondi, Betsy A. Hirsch, Janet Franklin, Beverly Lange, Alan S. Gamis, Todd A. Alonzo, Soheil Meshinchi
Journal: Blood (2010)
P1.02-082 The Feasibility of Cell-Free DNA Sequencing for Mutation Detection in Non–Small Cell Lung Cancer Was Determined by Tumor Volume
Authors: Tatsuo Ohira, Kazuko Sakai, Sachio Maehara, Maeda Junichi, Koichi Yoshida, Masaru Hagiwara, Masatoshi Kakihana, Tetsuya Okano, Naohiro Kajiwara, Kazuto Nishio, Norihiko Ikeda
Journal: Journal of Thoracic Oncology (2017)
P258 Infant lung function testing: a new approach using a rapid, portable system for measuring lung clearance index (LCI) in health and disease
Authors: A Shawcross, CS Murray, J Kirkby, J Miles, K Pike, S Rees, P Aurora, A Horsley
Journal: Thorax (2016)

<h3>Introduction</h3> Lung clearance index (LCI) is a sensitive measure of lung disease in infants, with potential applications in clinical practice and research. However, measuring LCI in infants is technically challenging and there is no simple method of assessing LCI outside of specialist research laboratories in this population. We have previously described an alternative method of measuring LCI, in which expired gas is collected and analysed to derive functional residual capacity (FRC) and LCI without directly measuring flow. This eliminates one of the major technical challenges, whilst also reducing the system’s dead space. This method is highly accurate <i>in vitro</i>, with a mean accuracy of FRC measurement to within 1%, down to FRC of 100ml.<sup>1</sup> The method does not require large external gas tanks, and washout is performed breathing room air, making the system fully portable. <h3>Aim</h3> To assess the performance of this method <i>in vivo.</i> <h3>Method</h3> Healthy controls and infants with CF are currently being recruited to undergo LCI measurement using this method. Practical applicability of the system is determined by the number of successful tests and within-subject repeatability, defined as coefficient of variation (CV%) of same-visit repeats. Comparison will be made with LCI measurements obtained using a respiratory mass spectrometer, currently considered the gold standard for infant LCI measurement. <h3>Results</h3> To date, 10 healthy controls (mean age 53 weeks) and 2 infants with CF (mean age 55 weeks) have successfully undergone LCI measurement using this method. Mean LCI in controls was 6.62 (range 5.79–7.91). Mean within-subject CV% was 5.9%. Mean LCI in infants with CF was 7.63 (CV 5%). <h3>Conclusion</h3> Preliminary data suggest this is a feasible and reproducible method of performing LCI in infants. Results in both infants with CF and controls fall within ranges predicted by the respiratory mass spectrometer<sup>2</sup> and within accuracy limits set by international guidelines. This could provide a more accessible alternative to current technologies, enabling this test to be offered in more centres. <h3>References</h3> Shawcross, <i>et al</i>. <i>Ped Pulmonol</i> 2016;<b>51</b>:491–497. Lum, <i>et al</i>. <i>Eur Respir J</i> 2013;<b>41</b>:1371–7.
Association between a validated symptom assessment tool and nurse clinical impression in patients with cancer admitted to a palliative care unit.
Authors: W. Rhondali, D. Hui, S. H. Kim, K. L. Kilgore, J. H. Kang, L. M. T. Nguyen, E. Bruera
Journal: Journal of Clinical Oncology (2011)

9112 Background: Advanced cancer inpatients develop multiple severe symptoms. Effective treatment is only possible if appropriate assessments took place. Most clinicians do not routinely use symptoms assessment tools in everyday practice and treat according to their clinical impression only. In this prospective study, we compared the patient reported symptom battery by the Edmonton Symptom Assessment System (ESAS) to bedside nurses’ clinical impression. Methods: Consecutive advanced cancer inpatients admitted to our Acute Palliative Care Unit from April to July 2010 were included. We collected the results from ESAS (10 symptoms: pain, nausea, fatigue, drowsiness, appetite, shortness of breath, sleep, depression, anxiety, feeling of well being rated from 0 to 10) on the day of admission (D1) and on the third day of hospitalization (D3). We also collected the nurses’ clinical impression of patient’s physical and emotional distress on D1 and D3 (none=0, severe=3). Results: 118 patients completed the ESAS on day 1 and 116 on day 3. We found that for D1 there was no significant association between nurses’ perception of symptoms burden and ESAS assessment. The median ESAS physical and psychosocial scores were 31 and 12 in patients with nurse clinical impression of low or no physical distress, versus 34 (p=0.07) and 15 (p=0.18) in patients with nurse clinical impression of moderate or severe distress, respectively. For D3, we found a significant association only for pain (r =0.31, p=0.001) and anxiety (r =0.29, p=0.001). On D1, the nurses’ assessment had low sensitivity as compared to ESAS (cut off score of 5 for fatigue, 2 for depression and anxiety, and 4 for all others) ranging from 0.56 to 0.69, and low specificity ranging from 0.43 and 0.58, without significant improvement on day 3. Conclusions: The clinical impression of highly trained palliative care nurses had no significant association with patient reported ESAS scores. Validated tools are needed for daily clinical assessment of physical and psychosocial distress in advanced cancer patients.
P2.02-043 Randomized Ph II Trial of Allogeneic DPV-001 Cancer Vaccine Alone or with Adjuvant for Curatively-Treated Stage III NSCLC
Authors: Rachel Sanborn, Brian Boulmay, Rui Li, Kyle Happel, Sachin Puri, Christopher Paustian, Christopher Dubay, Sandra Aung, Brenda Fisher, Carlo Bifulco, Keith Bahjat, Yoshinobu Koguchi, Augusto Ochoa, Hong-Ming Hu, Traci Hilton, Bernard Fox, Walter Urba
Journal: Journal of Thoracic Oncology (2017)
Bugging Tumors
Authors: Robert M. Hoffman
Journal: Cancer Discovery (2012)

Abstract Summary: The effects of bacteria on patients with cancer have been observed for at least two centuries. Recent studies in animal models of cancer have shown efficacy of both anaerobic bacteria such as Clostridia and Bifidobacteria and facultative anaerobes such as Salmonella. In this issue of Cancer Discovery, Flentie and colleagues have identified five Salmonella promoters that are specifically stimulated by cancer cells as well as by acidic pH, a property of most tumors. One of these promoters (STM1787) was linked to a Shiga toxin gene and inserted in a wild-type Salmonella typhimurium strain, which showed in vivo antitumor efficacy. Approaches to further improving the efficacy of S. typhimurium with the use of tumor-targeting mutations are discussed. Because the barriers to efficacy of standard therapy of cancer appear to be opportunities for bacterial cancer therapy, the future of bacterial therapy of cancer appears bright. Cancer Discov; 2(7); 588–90. ©2012 AACR. Commentary on Flentie et al., p. 624.